To: jmcnmt@yahoo.com
Subject: Request for Additional Information in Support of NRC License Renewal

From: Lester Tripp
USNRC Region 1

To: Joshua Mussaf, CNMT
Alfieri Cardiology, P.A.

Re: Request for Additional Information in Support of License Renewal
License No. 07-28154-01
Control No. 581465

Date: November 20, 2013

Dear Mr. Mussaf:

This correspondence is in reference to your application dated July 26, 2013, requesting renewal of your NRC License No. 07-28154-01. In order to continue our review of your application, we need the following information:

1. Your current License Amendment No. 7 specifies the name of your facility as *Alfieri Cardiology, P.A., d.b.a. Delaware SPECT Imaging.* On NRC Form 313, your application states that the name of your facility is *Alfieri Cardiology P.A.* Please specify the correct name of your facility. Also state whether there has been a change of control/ownership of your facility.

2. Your current License Amendment No. 7 authorizes the possession and use of radiopharmaceuticals permitted by 10 CFR 35.100 and 10 CFR 35.200. In items Number 5 and Number 6 of your renewal application you request only 10 CFR 35.200. Do you want to discontinue authorization for possession and use of radiopharmaceuticals permitted by 10 CFR 35.100?

3. Item 7, paragraph 4 of your application, refers to 10 CFR 20.110. The correct reference is 10 CFR 20.1101. Please confirm that you have developed and will implement and maintain written procedures for safe response to spills of licensed material in accordance with 10 CFR 20.1101.

4. Item 7, paragraph 5 of your application, should specify that the required procedures will be *written.* Please confirm that you have developed and will implement and maintain *written* procedures for safe use of unsealed byproduct material that meet the requirements of 10 CFR 20.1101 and 10 CFR 20.1301.

5. Item 7, paragraph 2 of your application, references *Appendix N Model Procedures for Developing, Maintaining, and Implementing Written Directives.* (Written directive references are in Appendix S). Written Directives are only required for certain therapeutic use of license material, therefore no confirmation involving written directives is required.

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select Nuclear Materials; Med, Ind, & Academic Uses; then Licensee Toolkits, see our toolkit index page. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 8:00a.m. to 5:30p.m. EST, Monday through Friday (except Federal holidays).

We will continue our review upon receipt of this information. Please reply to my attention at the Region I Office and refer to Mail Control No. 581465. If you have any technical questions regarding this deficiency letter, please call me at (610) 337-5358. Please have the response to this correspondence signed by Dr. Alfieri.

In order to continue prompt review of your application, we request that you submit your response to this letter within 15 calendar days from the date of this correspondence.

Lester Tripp
Health Physicist
Medical Branch
Division of Nuclear Materials Safety